Return to homepagePandemic Pact

Niclosamide Intramuscular Depot Injection for Dengue Virus Disease

Grant number: 7662

Grant search

Key facts

  • Disease

    Dengue

  • Start & end year

    2021
    2021

  • Known Financial Commitments (USD)

    $313,020

  • Funder

    RIGHT Foundation

  • Principal Investigator

    N/A

  • Research Location

    41

  • Lead Research Institution

    Daewoong Therapeutics

  • Research Priority Alignment

    N/A

  • Research Category

    N/A

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Daewoong Therapeutics aims to repurpose niclosamide as an intramuscular depot injection effective against all four serotypes of dengue virus. This project assesses the activity of the compounds on dengue serotypes and performs in vivo efficacy studies in a dengue mouse model. The development of these therapeutics against the dengue virus is in response to the lack of available dengue treatments, and would be a complementary option to vaccines.

2 Publications linked via Europe PMC

Last Updated:6 days ago

View all publications at Europe PMC

DNA methylation of the KLK8 gene in depression symptomatology.

Neuropsin in mental health.